Summary
The prognostic value of estrogen receptor determination was studied for 510 stage I (axillary node negative) breast cancer patients treated by mastectomy alone.
Results at 60 months after mastectomy indicate that stage I patients whose tumors lack estrogen receptors fall into a significantly poorer prognostic group for both recurrence and survival than those whose tumors contain estrogen receptors.
Within the postmenopausal group, estrogen receptor negative (ER −) patients are recurring more rapidly than estrogen receptor positive (ER +) patients. Within the premenopausal group, ER + patients have a recurrence rate identical to ER− patients, which is apparent only after prolonged follow-up.
In contrast to postmenopausal ER + patients, premenopausal ER + patients appear to have no prognostic advantage over the ER − patients, and thus constitute a high risk group for which adjuvant endocrine therapy might prove beneficial.
This is a preview of subscription content, log in via an institution to check access.
References
Blamey RW, Bishop HM, Blake JRS, Doyle PJ, Elston CW, Haybittle JL, Nicholson RI, Griffiths K: Relationship between primary breast tumor receptor status and patient survival. Cancer 46: 2765–2769, 1980
Block GE, Ellis RS, DeSombre E, Jensen E: Correlation of estrophilin content of primary mammary cancer to eventual endocrine treatment. Ann Surg 188: 372–376, 1978
Cooke T, George D, Shields R, Maynard P, Griffiths K: Oestrogen receptors and prognosis in early breast cancer. Lancet 1: 995–997, 1979
Furmanski P, Saunders DE, Brooks SC, Rich MA: The prognostic value of estrogen receptor determinations in patients with primary breast cancer: an update. Cancer 46: 2794–2746, 1980
Gapinski PV, Donegan WL: Estrogen receptors and breast cancer: prognostic and therapeutic implications. Surgery 88: 386–393, 1980
Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52: 203–233, 1965
Hähnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44: 671–675, 1979
Hilf R, Feldstein ML, Gibson SL, Savlov ED: The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 45: 1993–2000, 1980
Hubay CA, Pearson OH, Marshall JS et al.: Adjuvant therapy of Stage II breast cancer: 48 month follow-up of a prospective randomized clinical trial. Breast Cancer Res Treat 1: 77–82, 1981
Kinne DW, Ashikari R, Butler A, Menendex-Botet C, Rosen PP, Schwartz M: Estrogen receptor protein value in breast cancer as a predictor of recurrence. Cancer 47: 2364–2367, 1981
Knight WA, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669–4671, 1977
Leake RE, Laing L, Calman KC, Macbeth FR, Crawford D, Smith DC: Oestrogen receptor status and endocrine therapy of breast cancer: response rates and status stability. Br J Cancer 43: 59–66, 1981
Lenzhofer R, Rainer H, Moser K, Jakesz R, Kolb R, Reiner G, Bettelheim P, Mörz R, Spona J, Bieglmayer CH, Chaput B: Prognostic significance of estrogen receptors in breast cancer.In SE Salmon and SE Jones (eds): Adjuvant Therapy of Cancer III. Grune and Stratton, New York, 1981, pp 313–319
Manni A, Arafah B, Pearson OH: Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy. Cancer (Suppl) 46: 2838–2841, 1980
Maynard PV, Blamey RW, Elston CW, Haybittle JL, Griffiths K: Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res 38: 4292–4295, 1978
McGuire WL, Carbone PP, Sears ME, Escher GC: Estrogen receptors in human breast cancer: an overview.In WL McGuire, PP Carbone, EP Vollmer (eds): Estrogen Receptors in Human Breast Cancer. Raven Press, New York, 1975, pp 1–7
Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884–2888, 1980
Samaan NA, Buzdar AU, Aldinger KA, Schultz PN, Yang KP, Romsdahl MM, Martin R: Estrogen receptor: a prognostic factor in breast cancer. Cancer 47: 554–560, 1981
Valagussa P, DiFronzo G, Bignami P, Buzzoni R, Bonadonna G, Veronesi U: Prognostic importance of estrogen receptors to select node negative patients for adjuvant chemotherapy.In SE Salmon and SE Jones (eds): Adjuvant Therapy of Cancer III. Grune and Stratton, New York, 1981, pp 329–333
Walt AJ, Singhakowinta A, Brooks SC, Cortez A: The surgical implications of estrophile protein estimations in carcinoma of the breast. Surgery 80: 506–512, 1976
Author information
Authors and Affiliations
Consortia
Additional information
Participating Investigators: Frank M. Barry, M.D., A.M. Cooperman, M.D., Ludwig Deppisch, M.D., Robert L. Druet, M.D., Caldwell Esselstyn, M.D., Y.S. Fu, M.D., Vernon D. Hacker, M.D., Harold B. Houser, M.D., Ezra Steiger, M.D. and Elden C. Weckesser, M.D.
Rights and permissions
About this article
Cite this article
Crowe, J.P., Hubay, C.A., Pearson, O.H. et al. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Tr 2, 171–176 (1982). https://doi.org/10.1007/BF01806453
Issue Date:
DOI: https://doi.org/10.1007/BF01806453